Jinxin Fertility Group Limited (1951.HK)

HKD 2.84

(-2.41%)

Market Cap (In HKD)

7.81 Billion

Revenue (In HKD)

2.78 Billion

Net Income (In HKD)

344.72 Million

Avg. Volume

11.03 Million

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.05-4.64
PE
-
EPS
-
Beta Value
1.357
ISIN
KYG5140J1013
CUSIP
G5140J101
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Care Facilities
CEO
Mr. Yang Dong
Employee Count
-
Website
https://www.jxr-fertility.com
Ipo Date
2019-06-25
Details
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; medical services in the areas of gynecology, urology, and internal medicine; ambulatory surgery center facilities services; and ancillary medical services. Further, it offers pre-implantation genetic screening testing services; and engages in the investment management and management consultancy, and real estate development and operation activities. Jinxin Fertility Group Limited was founded in 2003 and is headquartered in Chengdu, China.